Phaseline

Companies › Korea United Pharm.

Korea United Pharm.: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UIC202502–Phase 1Dyslipidemia–
UIC202505–Phase 1Dyslipidemia–
UIC202601–Phase 1Hypertension–
UIC202602–Phase 1Hypertension–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07162441UIC202502Phase 1DyslipidemiaCardiovascularSep 2025
NCT07162441UIC202505Phase 1DyslipidemiaCardiovascularSep 2025
NCT07682948UIC202601Phase 1HypertensionCardiovascularSep 2026
NCT07682948UIC202602Phase 1HypertensionCardiovascularSep 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.